

Number: MED 272	Date: May 2, 2024	
Subject: Ustekinumab added to Alberta Biosimilars Initiative	Reference: Alberta Drug Benefit List	

To: all practitioners and billing staff

On May 1, 2024, the Alberta Biosimilar Initiative was updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

Addition of ustekinumab biosimilars – all adult patients on Stelara must switch by November 1, 2024.

On May 1, 2024, two new ustekinumab biosimilar drugs, Jamteki and Wezlana were listed on the Alberta Drug Benefit List (ADBL) for the treatment of plaque psoriasis and will be subject to the Alberta Biosimilar Initiative.

Effective May 1, 2024, all Special Authorization requests for new ustekinumab starts, for the above indication, will be provided with a biosimilar version of ustekinumab. Adult patients currently taking Stelara will be required to switch to a biosimilar version by November 1, 2024, to maintain coverage through their Alberta government-sponsored drug plan.

If you require a list of your patients who are currently taking ustekinumab or require additional information on biosimilars, please visit the providers section of the Alberta Blue Cross [website](#) for forms and resources.

Contact: Sandra Rees, Director Professional and Industry Relations, Pharmaceutical and Health Benefits Branch	Approved by: Andrea Nagle
Telephone: 780-427-0866	Position: Executive Director, Pharmaceutical and Health Benefits Branch